Author:
Rahko E,Blanco G,Soini Y,Bloigu R,Jukkola A
Reference25 articles.
1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women;Lancet,1992
2. TP53 Mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer;Overgaard;Acta Oncol.,2000
3. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients;Knoop;J. Clin. Oncol.,2001
4. P53 determination alongside classical prognostic factors in node-negative breast cancer;Ferrero;Ann Oncol.,2000
5. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma. A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14–30 Years;Reed;Cancer,2000
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献